新冠大流行对儿童动脉缺血性卒中的影响:一项非预期自然实验
VIPS II前瞻性队列研究在北美和澳大利亚22个中心纳入205例儿童动脉缺血性卒中(AIS),其中100例处于新冠大流行期(2020年1月至2022年1月),并纳入100例无卒中健康儿童(39例处于大流行期)。大流行期AIS病例较无大流行期更少近期临床感染(17% vs 30%,P=0.02),但SARS-CoV-2抗体阳性率更高(26% vs 大流行期健康儿童10%,P=0.04)。结论认为大流行可能对儿童AIS有双重影响:公共卫生措施减少感染暴露的间接保护作用,以及新冠作为触发AIS的呼吸道病毒的 deleterious 效应。
要点
- 大流行期AIS病例较无大流行期更少近期临床感染(17% vs 30%,P=0.02)。
- 大流行期AIS病例SARS-CoV-2抗体阳性率26%(26/100),高于大流行期健康儿童的10%(4/39),P=0.04。
- 首例SARS-CoV-2阳性AIS病例出现于2020年7月。
核心结论
- 新冠大流行可能对儿童AIS有双重影响:公共卫生措施减少感染暴露的间接保护作用,以及新冠作为触发儿童AIS的呼吸道病毒的 deleterious 效应。
研究设计与样本
- VIPS II前瞻性队列研究,22个中心(北美、澳大利亚)于2016年12月至2022年1月纳入205例AIS儿童(28天至18岁),其中100例处于大流行期(2020年1月至2022年1月)。
- 另纳入100例无卒中健康儿童评估亚临床感染背景率,其中39例处于大流行期。
- 检测血清SARS-CoV-2核衣壳总抗体(感染后出现,非疫苗接种;半衰期3-6个月),并通过家长访谈评估临床感染。
主要发现
- 合格AIS病例月率从2020年春季至秋季下降,2021年初恢复,春季达峰。
- 大流行期与无大流行期病例相似,但大流行期病例前一个月临床感染更少(17% vs 30%;P=0.02),局灶性脑动脉病更多(20% vs 11%;P=0.09)。
- 大流行期AIS病例中26/100(26%)抗体阳性,大流行期健康儿童中4/39(10%)抗体阳性(P=0.04)。
- 首例SARS-CoV-2阳性病例出现于2020年7月;26例阳性AIS病例中10例(38%)家长报告近期感染,其中7例诊断为COVID-19;仅1例有儿童多系统炎症综合征。
- 抗体阳性AIS病例核衣壳IgG总水平中位数(IQR)为50.1 S/CO(26.9-95.3),抗体阳性健康儿童为18.8(12.0-101)(P=0.33)。
临床怎么用
- 儿童AIS评估中可考虑检测SARS-CoV-2核衣壳抗体以识别近期感染,尤其在大流行期。
- 家长报告近期感染在抗体阳性AIS病例中占38%,提示临床病史结合血清学可提高感染触发因素的识别。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The VIPS (Vascular Effects of Infection in Pediatric Stroke) II prospective cohort study aimed to better understand published findings that common acute infections, particularly respiratory viruses, can trigger childhood arterial ischemic stroke (AIS). The COVID-19 pandemic developed midway through enrollment, creating an opportunity to assess its impact. METHODS: Twenty-two sites (North America, Australia) prospectively enrolled 205 children (aged 28 days to 18 years) with AIS from December 2016 to January 2022, including 100 cases during the COVID-19 pandemic epoch, defined here as January 2020 to January 2022. To assess background rates of subclinical infection, we enrolled 100 stroke-free well children, including 39 during the pandemic. We measured serum SARS-CoV-2 nucleocapsid total antibodies (present after infection, not vaccination; half-life of 3-6 months). We assessed clinical infection via parental interview. RESULTS: The monthly rate of eligible AIS cases declined from spring through fall 2020, recovering in early 2021 and peaking in the spring. The prepandemic and pandemic cases were similar except pandemic cases had fewer clinical infections in the prior month (17% versus 30%; P=0.02) and more focal cerebral arteriopathy (20% versus 11%; P=0.09). Among pandemic cases, 26 of 100 (26%) had positive antibodies, versus 4 of 39 (10%) of pandemic-era well children (P=0.04). The first SARS-CoV-2 positive case occurred in July 2020. Ten of the 26 (38%) positive cases had a recent infection by parental report, and 7 of those 10 had received a diagnosis of COVID-19. Only 1 had multisystem inflammatory syndrome in children. Median (interquartile range) nucleocapsid IgG total levels were 50.1 S/CO (specimen to calibrator absorbance ratio; 26.9-95.3) in the positive cases and 18.8 (12.0-101) in the positive well children (P=0.33). CONCLUSIONS: The COVID-19 pandemic may have had dual effects on childhood AIS: an indirect protective effect related to public health measures reducing infectious exposure in general, and a deleterious effect as COVID-19 emerged as another respiratory virus that can trigger childhood AIS.
引用
- Fullerton HJ, Hills NK, Wintermark M, et al. Assessing the Impact of the COVID-19 Pandemic on Childhood Arterial Ischemic Stroke: An Unanticipated Natural Experiment. Stroke. 2025. PMID: 40171657. doi:10.1161/STROKEAHA.124.049909
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。